New triple therapy for the diagnosis of CKD-MBD: a cross-sectional study in Shanxi province.

Autor:	Zhao Z; Medical Record and Statistic Department, The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, China., Gao Y; Laboratory Animal Center, Shanxi Provincial Peoples Hospital, Taiyuan, Shanxi, China., Sui W; Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi, China., Zhang Z; Shanxi Hospital of Integrated Traditional Chinese and Western Medicine, Taiyuan, Shanxi, China., Feng L; Laboratory Animal Center, Shanxi Provincial Peoples Hospital, Taiyuan, Shanxi, China., Wang Z; Department of Anesthesiology, Shanxi Provincial Peoples Hospital, Taiyuan, Shanxi, China., Yang D; Department of Anesthesiology, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China., Zhou Y; Shanxi Hospital of Integrated Traditional Chinese and Western Medicine, Taiyuan, Shanxi, China langlang@sxmu.edu.cn zhouyun_sx@163.com rongshanli13@163.com.; Shanxi Genetic Engineering Center for Experimental Animal Models, The Fifth Hospital of Shanxi Medical University, taiyuan, shanxi, People's Republic of China., Li R; Shanxi Provincial Peoples Hospital, Taiyuan, Shanxi, China langlang@sxmu.edu.cn zhouyun_sx@163.com rongshanli13@163.com., Huang B; Laboratory Animal Center, Shanxi Provincial Peoples Hospital, Taiyuan, Shanxi, China langlang@sxmu.edu.cn zhouyun_sx@163.com rongshanli13@163.com.; Shanxi Hospital of Integrated Traditional Chinese and Western Medicine, Taiyuan, Shanxi, China.; Shanxi Genetic Engineering Center for Experimental Animal Models, The Fifth Hospital of Shanxi Medical University, taiyuan, shanxi, People's Republic of China.; Medical Sciences, UCSI University, Kuala Lumpur, Malaysia.; Shanxi University of Chinese Medicine, taiyuan, shanxi, People's Republic of China.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2024 Aug 17; Vol. 14 (8), pp. e081485. Date of Electronic Publication: 2024 Aug 17.
DOI:	10.1136/bmjopen-2023-081485
Abstrakt:	Objectives: To seek a triple combination of biomarkers for early diagnosis of chronic kidney disease-mineral and bone metabolic disorder and to explore the diagnostic efficacy of β2-microglobulin, parathyroid hormone and blood urea nitrogen in chronic kidney disease-mineral and bone metabolic disorder. Participants: We collected medical records of 864 patients with chronic kidney disease (without direct contact with patients) and divided them into two groups based on the renal bone disease manifestations of all patients. Primary and Secondary Outcome Measures: There were 148 and 716 subjects in the Chronic kidney disease-mineral and bone metabolic disorder and the control groups, respectively. The aggregated data included basic information and various clinical laboratory indicators, such as blood lipid profile, antibody and electrolyte levels, along with renal function-related indicators. Results: It was observed that most renal osteopathy occurs in the later stages of chronic kidney disease. In the comparison of two clinical laboratory indicators, 16 factors were selected for curve analysis and compared. We discovered that factors with high diagnostic values were β2-microglobulin, parathyroid hormone and blood urea nitrogen. Conclusions: The triple combination of β2-microglobulin+parathyroid hormone+blood urea nitrogen indicators can play the crucial role of a sensitive indicator for the early diagnosis of chronic kidney disease-mineral and bone metabolic disorder and in preventing or delaying the progress of chronic kidney disease-mineral and bone metabolic disorder. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu